Prelude Therapeutics
PublicPrelude Therapeutics is now publicly traded
The data on this page reflects Prelude Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Seed
Nov 13, 2024
Total Funding Raised
$155M
Company Overview
Prelude Therapeutics is a clinical-stage precision oncology company that discovers and develops small molecule therapies and protein degraders for cancers with high unmet needs. Founded in 2016, the company leverages its expertise in cancer biology and medicinal chemistry to create new chemical entities. Its pipeline includes several drug candidates in clinical development, such as PRT3789 (a SMARCA2 degrader), PRT2527 (a CDK9 inhibitor), and PRT3645 (a CDK4/6 inhibitor). The company is also developing next-generation degrader antibody conjugates (Precision ADCs). Prelude Therapeutics is a public company trading on the Nasdaq stock exchange under the ticker symbol PRLD.
Sector
Healthcare
AI Layer
Non-AI
Keywords
Prelude Therapeutics Comparables
Compare Prelude Therapeutics with similar companies based on industry and business-model similarity.
Prelude Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Nov 13, 2024 | ||||
| Follow-on Offering | Dec 11, 2023 | ||||
| VC Round | Aug 24, 2020 | ||||
| VC Round | Jun 12, 2019 | ||||
| Growth Equity | Oct 20, 2017 |
Prelude Therapeutics Investors
Notable investors and investment history
Prelude Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |